Diabetes News

In 2020 — the last year of the study period — researchers estimated that one in 10 new cases of type 2 diabetes mellitus could be connected to the intake of sugar-sweetened beverages.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation.

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with cardiometabolic syndrome at baseline, a speaker reported.

Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.

In patients with hypercortisolism and difficult-to-control type 2 diabetes, mifepristone lowered HbA1c at 24 weeks compared with placebo, researchers reported at World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

Diabetes and prediabetes were significantly associated with decreased life expectancy and increased risk for all-cause, cardiovascular disease and cancer mortality among Chinese adults, according to findings published in Diabetes Care.

Most adults who lose weight as part of obesity therapy should not experience sarcopenia due to a decrease in fat-free mass, but more research is needed on the impact of GLP-1 receptor agonists and similar drugs on older adults.

Individuals with diabetes who were hospitalized for non-ST elevation myocardial infarction had significantly higher risk for long-term mortality compared with individuals without diabetes, according to new research.

Continuous glucose monitoring can lower mortality risk in addition to improving glycemic control for people with diabetes, according to a speaker at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.